Difference between revisions of "Talk:Case 52"

From Libre Pathology
Jump to navigation Jump to search
m (? broader range of IHC for this case)
(changes made)
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
The list of IHC for which Dr Torres asks why includes the following choices that I think are reasonable  
The list of IHC for which" Dr Torres asks why" includes the following choices that I think are reasonable  
*CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
*CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
*Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
*Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
*PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
*PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
::[https://librepathology.org/w/index.php?title=Case_52&diff=47416&oldid=29649 Changes were made] to the case as result of the comments. [[User:Michael|Michael]] ([[User talk:Michael|talk]]) 12:10, 23 May 2017 (EDT)

Latest revision as of 16:11, 23 May 2017

The list of IHC for which" Dr Torres asks why" includes the following choices that I think are reasonable

  • CD56 - generally considered the most sensitive neuroendocrine marker (and least specific), routinely we use CD56, synaptophysin, CrgA, and...
  • Ki67 - useful for assessing mitotic activity in typical vs atypical carcinoids
  • PanCK or AE1/AE3: Given the differential includes an adeno I think a cytokeratin would be reasonable
Changes were made to the case as result of the comments. Michael (talk) 12:10, 23 May 2017 (EDT)